Product Pipeline
| Programs Under Development | Branded Products (a) | Therapeutic Category | NDA / ANDA | Development Stage (b) | Partnered |
| ELI-154 Oxycodone CR Once a day | NA | Pain | NDA | Phase III pending | No |
| ELI-216 Abuse Resistance Product for use with oxycodone or other opioids | N/A | Pain | NDA | Phase III pending | No |
| Undisclosed Twice a day | Undisclosed | Anti-infective | ANDA | Pilot BE study complete | No |
| Undisclosed Once a day | Undisclosed | Gastrointestinal | ANDA | Pilot BE study complete | Yes |
| Commercial Products | |||||
| Commercial Product | Branded Products (a) | Therapeutic Category | Commercial Status | Partner | |
| Lodrane® Once a Day | N/A | Allergy | Launched | ECR Pharmaceuticals | |
| Lodrane 24D ® Once a day | N/A | Allergy | Launched | ECR Pharmaceuticals | |
| Phentermine HCl 37.5 mg tablets | Adipex-P® 37.5 mg | Bariatric | Launched | Precision Dose, Inc. / TAGI | |
| Hydromorphone Hydrochloride 8 mg tablets | Dilaudid® 8 mg | Pain | FDA Approved, Launch pending | Precision Dose, Inc. / TAGI | |
| Naltrexone Hydrochloride 50 mg | ReVia® and Depade® | Opioid Receptor Antagonist | FDA Approved, Launch pending | Precision Dose, Inc. / TAGI | |
No comments:
Post a Comment